CAPLYTA drives stock potential amid market expansion By Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:), a biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, has been making significant strides in the market with its flagship product, CAPLYTA (lumateperone). The company’s performance and future prospects have garnered attention from analysts, who see potential for substantial growth in the coming years.
Company Overview and Market Position
Intra-Cellular Therapies has established itself as a key player in the psychiatric and neurological treatment space, primarily through the success of CAPLYTA. This atypical antipsychotic drug, currently approved for the treatment of schizophrenia and bipolar disorder, has been gaining traction due to its…
